Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Betamethasone Valerate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 13/20 | 1.00 |
| ▸ | PGR | P06401 | 4/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 4/20 | 1.00 |
| ▸ | USP2 | O75604 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | MMP1 | P03956 | 10/20 | 0.81 |
| ▸ | LMNA | P02545 | 2/20 | 0.75 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.75 |
| ▸ | MAPT | P10636 | 2/20 | 0.75 |
| ▸ | MLNR | O43193 | 1/20 | 0.75 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.75 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.75 |
| ▸ | PPARG | P37231 | 1/20 | 0.75 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.75 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.75 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.75 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.75 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.74 |
| ▸ | DRD2 | P14416 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Betamethasone Valerate SCHEMBL29407278 | 1.00 | NR3C1 (1.00) | NR3C1PGRCYP3A4USP2MEN1 | |
| Betamethasone Valerate SCHEMBL9768484 | 1.00 | NR3C1 (1.00) | NR3C1PGRCYP3A4USP2MEN1 | |
| Betamethasone Valerate SCHEMBL9768470 | 1.00 | NR3C1 (1.00) | NR3C1PGRCYP3A4USP2MEN1 | |
| Betamethasone Valerate SCHEMBL16243364 | 1.00 | NR3C1 (1.00) | NR3C1PGRCYP3A4USP2MEN1 | |
| Betamethasone Valerate SCHEMBL11051241 | 1.00 | NR3C1 (1.00) | NR3C1PGRCYP3A4USP2MEN1 | |
| Betamethasone Valerate SCHEMBL14339607 | 1.00 | NR3C1 (1.00) | NR3C1PGRCYP3A4USP2MEN1 | |
| Betamethasone Valerate SCHEMBL7564753 | 1.00 | NR3C1 (1.00) | NR3C1PGRCYP3A4USP2MEN1 | |
| Betamethasone Valerate SCHEMBL14339612 | 1.00 | NR3C1 (1.00) | NR3C1PGRCYP3A4USP2MEN1 | |
| Dexamethasone Valarate SCHEMBL124723 | 1.00 | NR3C1 (1.00) | NR3C1PGRCYP3A4USP2MEN1 | |
| Betamethasone Valerate SCHEMBL9768466 | 1.00 | NR3C1 (1.00) | NR3C1PGRCYP3A4USP2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 844 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116507626-A | Compositions and methods for modulating short-chain dehydrogenase activity | 罗迪奥治疗公司 | 2023-07-28 | — | — | CN | claimed |
| US-20230192717-A1 | COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY | CASE WESTERN RESERVE UNIVERSITY | 2023-06-22 | — | — | US | claimed |
| EP-4153299-A1 | COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY | Rodeo Therapeutics Corporation (US) | 2023-03-29 | — | — | EP | claimed |
| US-20230039604-A1 | COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY | RODEO THERAPEUTICS CORPORATION | 2023-02-09 | — | — | US | claimed |
| US-20210401798-A1 | LIPOXIN A4 ANALOGS AND USES THEREOF | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2021-12-30 | — | — | US | claimed |
| WO-2021236779-A1 | COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY | RODEO THERAPEUTICS CORPORATION (US) | 2021-11-25 | — | — | WO | claimed |
| CN-113507931-A | Compositions and methods for modulating short-chain dehydrogenase activity | 卡斯西部储备大学 | 2021-10-15 | — | — | CN | claimed |
| EP-3883577-A1 | COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY | CASE WESTERN RESERVE UNIVERSITY (US) | 2021-09-29 | — | — | EP | claimed |
| CN-112334128-A | Pharmaceutical composition containing dexpanthenol and polyhexamethylene guanidine | 巴伐利亚专利联盟有限责任公司 | 2021-02-05 | — | — | CN | claimed |
| CN-111132982-A | Compositions and methods for modulating short-chain dehydrogenase activity | 卡斯西部储备大学 | 2020-05-08 | — | — | CN | claimed |
| WO-2001041746-A1 | ANTI ITCH PATCH | LECTEC CORPORATION (US) | 2001-06-14 | — | — | WO | claimed |
| US-5681584-A | SOLID CORE OF ACTIVE AGENT, SOLUBLE DELAY JACKET COATING, SEMIPERMEABLE MEMBRANE, AND ADDITIONAL LAYER OF ACTIVE AGENT | CIBA-GEIGY CORPORATION (US) | 1997-10-28 | — | — | US | claimed |
| EP-0484529-B1 | SKIN CREAM PREPARATION FOR EXTERNAL USE | HISAMITSU PHARMACEUTICAL CO (JP) | 1994-04-27 | — | — | EP | claimed |
| US-5219877-A | Fungicide. antiinflammatory agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 1993-06-15 | — | — | US | claimed |
| EP-0170642-A2 | Liposomes containing steroid esters | Aktiebolaget Draco (SE) | 1986-02-05 | — | — | EP | claimed |
| US-4473565-A | CORTICOSTEROID AND NON-STEROIDAL AGENT | JOHNSON & JOHNSON (US) | 1984-09-25 | — | — | US | claimed |
| US-4360518-A | MEFENAMIC OR FLUFENAMIC ACID WITH CORTICOSTEROID | JOHNSON & JOHNSON (US) | 1982-11-23 | — | — | US | claimed |
| US-4350690-A | TOPICAL ANTIINFLAMMATORY AGENTS | CRESSINGTON INVESTMENTS LTD. (HK) | 1982-09-21 | — | — | US | claimed |
| US-4282216-A | Topical anti-inflammatory drug therapy | JOHNSON & JOHNSON (US) | 1981-08-04 | — | — | US | claimed |
| US-4185100-A | CORTICOSTEROID AND A HYDROTROPIC ACID DERIVATIVE, ENZYME INHIBITORS | JOHNSON & JOHNSON (US) | 1980-01-22 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210401798-A1 | LIPOXIN A4 ANALOGS AND USES THEREOF | LTA4H, ALOX15B, LTB4R | NR3C1 736/4885PGR 3400/4885CYP3A4 423/4885 |
| US-20230039604-A1 | COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY | HPGD, GCDH, HPGDS | NR3C1 1540/4885PGR 1321/4885CYP3A4 1086/4885 |
| US-20230192717-A1 | COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY | HPGD, GCDH, HPGDS | NR3C1 1540/4885PGR 1321/4885CYP3A4 1086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.